Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA
May 02, 2013 09:01 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 2, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the U.S. Food and Drug Administration (FDA) yesterday notified the company...
Hyperion Therapeutics Exercises Option to Acquire Rights to BUPHENYL(R) and AMMONUL(R)
May 02, 2013 09:00 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 2, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the exercise of its option to acquire BUPHENYL®(sodium phenylbutyrate)...
Hyperion Therapeutics to Present at Needham's 12th Annual Healthcare Conference
April 25, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 25, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at Needham's 12th Annual Healthcare...
Hyperion Therapeutics Issued Key Patent Pertaining to Use of Fasting Ammonia
April 16, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 16, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the U.S. Patent & Trademark Office (USPTO) has issued to Hyperion...
Hyperion Therapeutics Completes Follow-On Offering and Announces Exercise of Underwriters' Over-Allotment Option
March 13, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 13, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today the completion of its follow-on offering of 2,875,000 shares of common stock....
Hyperion Therapeutics Announces Pricing of Follow-On Offering
March 08, 2013 09:15 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 8, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today the pricing of its follow-on offering of 2,875,000 shares of its common stock...
Hyperion Makes RAVICTI(TM) Available for Shipment to UCD Patients
February 28, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that RAVICTI™ (glycerol phenylbutyrate) Liquid is now available for...
Hyperion Therapeutics Announces Fourth Quarter and Full Year 2012 Operating Results
February 25, 2013 06:23 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported financial operating results for the fourth quarter and the year ended December...
Hyperion Therapeutics to Present at the Leerink Swann Global Healthcare Conference
February 08, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Leerink Swann Global Healthcare...
Hyperion Therapeutics' RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders
February 01, 2013 15:00 ET
|
Hyperion Therapeutics, Inc.
Anticipated market launch by end of April 2013
Patent allowance extends coverage to 2032
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc....